Published in PLoS Med on September 27, 2011
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract (2014) 2.27
Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf (2013) 2.15
Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation (2014) 2.11
Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med (2012) 1.71
Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf (2012) 1.50
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A (2012) 1.35
Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med (2013) 1.19
Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol (2014) 1.15
New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res (2015) 1.04
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol (2012) 1.03
Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol (2013) 1.02
Ethnopharmacological in vitro studies on Austria's folk medicine--an unexplored lore in vitro anti-inflammatory activities of 71 Austrian traditional herbal drugs. J Ethnopharmacol (2013) 0.95
Role of mesotherapy in musculoskeletal pain: opinions from the italian society of mesotherapy. Evid Based Complement Alternat Med (2012) 0.91
[Perioperative pain management for abdominal and thoracic surgery]. Schmerz (2014) 0.89
Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf (2015) 0.89
Chronic low back pain: pharmacological, interventional and surgical strategies. Nat Rev Neurol (2013) 0.89
LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One (2013) 0.88
Risk of stroke in patients with rheumatism: a nationwide longitudinal population-based study. Sci Rep (2014) 0.87
The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology (2014) 0.87
Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. Eur J Clin Pharmacol (2012) 0.86
Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France. Br J Clin Pharmacol (2014) 0.86
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol (2014) 0.85
Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr Ther Res Clin Exp (2014) 0.82
Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice. Br J Pharmacol (2015) 0.82
Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries. J Gastroenterol (2013) 0.81
NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species. Oxid Med Cell Longev (2015) 0.80
Why drug safety should not take a back seat to efficacy. PLoS Med (2011) 0.80
Non-steroidal Anti-inflammatory Drugs (NSAIDs) Use in Primary Health Care Centers in A'Seeb, Muscat: A Clinical Audit. Oman Med J (2015) 0.80
Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis (2013) 0.80
[DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain]. Z Rheumatol (2016) 0.80
Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging (2016) 0.79
Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice. PLoS One (2012) 0.79
Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev Res (Phila) (2016) 0.78
Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in rats. PLoS One (2014) 0.78
Ischaemic cardiovascular risk and prescription of non-steroidal anti-inflammatory drugs for musculoskeletal complaints. Scand J Prim Health Care (2014) 0.78
COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One (2014) 0.78
Aspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test. FASEB J (2013) 0.78
Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther (2013) 0.78
Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. Front Immunol (2017) 0.78
Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study. PLoS One (2012) 0.78
Analysis of non-steroidal anti-inflammatory drug use in hospitalized patients and perception of their risk. Interdiscip Toxicol (2013) 0.77
NSAIDs and Colorectal Cancer Control: Promise and Challenges. Curr Pharmacol Rep (2015) 0.77
Piroxicam-β-cyclodextrin: a GI safer piroxicam. Curr Med Chem (2013) 0.77
Impairment of aspirin antiplatelet effects by non-opioid analgesic medication. World J Cardiol (2015) 0.77
Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs (2015) 0.77
The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther (2013) 0.76
The safety and efficacy of an enzyme combination in managing knee osteoarthritis pain in adults: a randomized, double-blind, placebo-controlled trial. Arthritis (2015) 0.76
Initial treatment of complete rotator cuff tear and transition to surgical treatment: systematic review of the evidence. Muscles Ligaments Tendons J (2016) 0.75
2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation. Hypertens Res (2016) 0.75
Use and abuse of medication during 2014 FIFA World Cup Brazil: a retrospective survey. BMJ Open (2015) 0.75
Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management. Clin Transl Sci (2015) 0.75
Effect of new polyherbal formulations DF1911, DF2112 and DF2813 on CFA induced inflammation in rat model. BMC Complement Altern Med (2017) 0.75
An integrated safety analysis of intravenous ibuprofen (Caldolor(®)) in adults. J Pain Res (2015) 0.75
Cardiovascular safety of NSAIDs. Can Fam Physician (2014) 0.75
Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway. Cancer Sci (2016) 0.75
Anti‑inflammatory effects of oxymatrine on rheumatoid arthritis in rats via regulating the imbalance between Treg and Th17 cells. Mol Med Rep (2017) 0.75
Pharmacotherapies in Geriatric Chronic Pain Management. Clin Geriatr Med (2016) 0.75
Further Effort is Needed to Improve Management of Chronic Pain in Primary Care. Results from the Arkys Project. Clin Pract (2016) 0.75
Practice guidelines for pharmacists: The management of osteoarthritis. Can Pharm J (Ott) (2017) 0.75
Clinical Pharmacology and Cardiovascular Safety of Naproxen. Am J Cardiovasc Drugs (2016) 0.75
[Cardiovascular safety of celecoxib : Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)]. Internist (Berl) (2017) 0.75
Meloxicam and risk of myocardial infarction: a population-based nested case-control study. Rheumatol Int (2017) 0.75
Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults. Clin Rheumatol (2015) 0.75
Two release rates from monolithic carboxymethyl starch tablets: formulation, characterization, and in vitro/in vivo evaluation. Drug Deliv Transl Res (2017) 0.75
Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf (2017) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Interaction revisited: the difference between two estimates. BMJ (2003) 11.97
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (2011) 6.89
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med (2005) 6.32
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation (2011) 4.90
Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf (2006) 4.64
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther (1999) 2.10
Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med (2011) 2.06
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol (1998) 2.02
NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J (2006) 1.96
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol (2006) 1.90
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation (2004) 1.87
Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ (2006) 1.82
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med (2006) 1.71
Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes (2010) 1.56
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med (2007) 1.54
Further experience with indomethacin in the treatment of rheumatic disorders. Br Med J (1966) 1.33
Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum (2004) 1.24
NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One (2011) 1.04
What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf (2007) 1.01
Interactions between oxicams and membrane bilayers: an explanation for their different COX selectivity. Med Chem (2006) 0.82
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Selling sickness: the pharmaceutical industry and disease mongering. BMJ (2002) 10.98
Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res (2004) 7.20
Preventing overdiagnosis: how to stop harming the healthy. BMJ (2012) 6.74
What are the roles and responsibilities of the media in disseminating health information? PLoS Med (2005) 3.95
The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ (2010) 3.95
The fight against disease mongering: generating knowledge for action. PLoS Med (2006) 3.65
Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation (2010) 2.29
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 2.04
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens (2004) 1.90
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood (2006) 1.83
Describing treatment effects to patients. J Gen Intern Med (2003) 1.75
Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. Global Health (2005) 1.68
The free trade agreement between Australia and the United States. BMJ (2004) 1.62
Transfusion triggers: a systematic review of the literature. Transfus Med Rev (2002) 1.57
Suicide prevention as a community development process: understanding circumpolar youth suicide prevention through community level outcomes. Int J Circumpolar Health (2009) 1.54
Supporting families in a high-risk setting: proximal effects of the SAFEChildren preventive intervention. J Consult Clin Psychol (2004) 1.54
Coverage with evidence development: the Ontario experience. Int J Technol Assess Health Care (2011) 1.53
Cohort profile: The Hunter Community Study. Int J Epidemiol (2010) 1.50
Sequence, annotation, and analysis of synteny between rice chromosome 3 and diverged grass species. Genome Res (2005) 1.48
Media reporting of health interventions: signs of improvement, but major problems persist. PLoS One (2009) 1.43
What the public learns about screening and diagnostic tests through the media. Med J Aust (2012) 1.42
Assessment of awareness of connectedness as a culturally-based protective factor for Alaska native youth. Cultur Divers Ethnic Minor Psychol (2011) 1.32
Increasing the demand for childhood vaccination in developing countries: a systematic review. BMC Int Health Hum Rights (2009) 1.29
CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med (2012) 1.26
Family violence. Annu Rev Psychol (2006) 1.24
Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.22
Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med (2013) 1.19
Lesson from Canada's Universal Care: socially disadvantaged patients use more health services, still have poorer health. Health Aff (Millwood) (2011) 1.10
Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer (2010) 1.08
Feasibility of a community intervention for the prevention of suicide and alcohol abuse with Yup'ik Alaska Native youth: the Elluam Tungiinun and Yupiucimta Asvairtuumallerkaa studies. Am J Community Psychol (2014) 1.08
The benefits of booster interventions: evidence from a family-focused prevention program. Prev Sci (2009) 1.08
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther (2003) 1.02
Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer (2005) 1.00
A protective factors model for alcohol abuse and suicide prevention among Alaska Native youth. Am J Community Psychol (2014) 0.97
Misleading drug promotion--no sign of improvements. Pharmacoepidemiol Drug Saf (2004) 0.96
Multicultural Mastery Scale for youth: multidimensional assessment of culturally mediated coping strategies. Psychol Assess (2011) 0.94
Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med (2009) 0.93
Using linked health administrative data to assess the clinical and healthcare system impact of chronic diseases in Ontario. Healthc Q (2011) 0.93
Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships. Br J Clin Pharmacol (2006) 0.93
What drives health-care spending priorities? An international survey of health-care professionals. PLoS Med (2007) 0.92
Disease mongering is now part of the global health debate. PLoS Med (2008) 0.91
The brief family relationship scale: a brief measure of the relationship dimension in family functioning. Assessment (2011) 0.91
Examining lower urinary tract symptom constellations using cluster analysis. BJU Int (2008) 0.88
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. Br J Clin Pharmacol (2008) 0.88
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer (2012) 0.88
Does it matter who writes medical news stories? PLoS Med (2010) 0.87
Umyuangcaryaraq "Reflecting": multidimensional assessment of reflective processes on the consequences of alcohol use among rural Yup'ik Alaska Native youth. Am J Drug Alcohol Abuse (2012) 0.86
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo. Ann Surg Oncol (2009) 0.86
Patient co-payments and use of prescription medicines. Aust N Z J Public Health (2004) 0.86
Increasing parent involvement in youth HIV prevention: a randomized Caribbean study. AIDS Educ Prev (2009) 0.85
Trajectories of multiple adolescent health risk behaviors in a low-income African American population. Dev Psychopathol (2013) 0.83
A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist (2007) 0.83
Depression and exposure to suicide predict suicide attempt. Depress Anxiety (2013) 0.82
Empirical uncertainty and moral contest: a qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia. Soc Sci Med (2005) 0.82
The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high? Aust Health Rev (2013) 0.81
9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol (2003) 0.81
Moral hazard and prescription medicine use in Australia--the patient perspective. Soc Sci Med (2005) 0.81
Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer (2012) 0.81
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. Breast (2009) 0.81
HIV information and behavioral skills moderate the effects of relationship type and substance use on HIV risk behaviors among African American youth. AIDS Patient Care STDS (2013) 0.81
Lower extremity vascular stenting for a post-traumatic pseudoaneurysm in a young trauma patient. J Emerg Trauma Shock (2011) 0.81
Erythropoiesis-stimulating agents: friends or foes? Transfusion (2013) 0.80
Beyond the cluster: methodological and clinical implications in the Boston Area Community Health survey and EPIC studies. BJU Int (2008) 0.80
A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin (2012) 0.80
A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer (2009) 0.80
Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life. Oncology (2005) 0.80
Preclinical antitumor activity of a nanoparticulate SN38. Invest New Drugs (2013) 0.79
Selective COX-2 inhibitors: a promise unfulfilled? Gastroenterology (2007) 0.78
Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. J Child Adolesc Psychopharmacol (2011) 0.78
Single-enantiomer drugs: elegant science, disappointing effects. Clin Pharmacokinet (2004) 0.78
The role of the school environment in relational aggression and victimization. J Youth Adolesc (2012) 0.77
Ensuring the safety of new medications and devices: are naltrexone implants safe? Med J Aust (2008) 0.77
IQWiG methods--a response to two critiques. Health Econ (2010) 0.77
Patent law. Lancet (2003) 0.75
Medical research and the news media. N Engl J Med (2005) 0.75
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene. Br J Clin Pharmacol (2011) 0.75
Authors' response to letter to the editor. J Med Econ (2013) 0.75
Bridges to Iran. Lancet (2003) 0.75
Nurses' use of alcohol and other drugs: findings from a national probability sample. Subst Use Misuse (2002) 0.75
Anxiety and fear. Discriminant validity in the child and adolescent practitioner's perspective. Eur Child Adolesc Psychiatry (2002) 0.75
Big Data and Population Health: Focusing on the Health Impacts of the Social, Physical, and Economic Environment. Epidemiology (2017) 0.75
Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme. Int J Pharm Pract (2010) 0.75
Outbreak of Septic Arthritis Associated with Intra-Articular Injections at an Outpatient Practice - New Jersey, 2017. MMWR Morb Mortal Wkly Rep (2017) 0.75
First on-sky SCAO validation of full LQG control with vibration mitigation on the CANARY pathfinder. Opt Express (2014) 0.75
Combining freeform optics and curved detectors for wide field imaging: a polynomial approach over squared aperture. Opt Express (2017) 0.75
In conversation with David Henry. Interview by Ken Tremblay. Healthc Q (2007) 0.75
How to ascertain drug safety in the context of benefit. Controversies and concerns. J Rheumatol (2009) 0.75
Observations from the OMERACT Drug Safety Summit, May 2008. J Rheumatol (2009) 0.75
What's in store. Mark Health Serv (2005) 0.75